Skip to main content
. 2014 Aug 6;18(8):1519–1539. doi: 10.1111/jcmm.12278

Fig. 3.

Fig. 3

Forest plot showing pooled median PFS/TTP and 95% accuracy intervals with single-agent erlotinib, single-agent gefitinib or chemotherapy in patients with EGFR mutation-positive NSCLC in all lines of therapy. PFS: progression-free survival; TTP: time to progression; EGFR: epidermal growth factor receptor; NSCLC: non-small-cell lung cancer.